Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 1,452 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 1,452 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $25.47, for a total value of $36,982.44. Following the transaction, the insider owned 117,227 shares of the company’s stock, valued at approximately $2,985,771.69. This trade represents a 1.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.00, for a total value of $108,900.00.
• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.36, for a total value of $100,143.96.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The stock was sold at an average price of $23.38, for a total value of $89,942.86.
• On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $107,880.00.

Nurix Therapeutics Price Performance

NASDAQ:NRIX traded up $0.26 during trading hours on Tuesday, reaching $26.04. 1,323,331 shares of the stock were exchanged, compared to its average volume of 1,456,768. The stock has a market cap of $2.70 billion, a PE ratio of -7.55 and a beta of 1.79. Nurix Therapeutics, Inc. has a twelve month low of $8.19 and a twelve month high of $28.23. The firm has a 50 day moving average of $24.51 and a 200 day moving average of $19.07.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). The business had revenue of $9.04 million during the quarter, compared to analyst estimates of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. Equities research analysts anticipate that Nurix Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on NRIX. Stifel Nicolaus boosted their price target on shares of Nurix Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Morgan Stanley raised their price objective on Nurix Therapeutics from $36.00 to $38.00 and gave the company an “overweight” rating in a report on Tuesday, July 28th. Jefferies Financial Group lifted their target price on Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Wall Street Zen upgraded Nurix Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Robert W. Baird increased their price target on Nurix Therapeutics from $26.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, June 18th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.21.

Institutional Trading of Nurix Therapeutics

Hedge funds have recently made changes to their positions in the business. Nykredit A S bought a new position in shares of Nurix Therapeutics during the 2nd quarter worth approximately $32,000. Larson Financial Group LLC boosted its position in Nurix Therapeutics by 339.0% during the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after purchasing an additional 1,190 shares during the period. Intesa Sanpaolo Wealth Management acquired a new position in shares of Nurix Therapeutics in the fourth quarter valued at $31,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Nurix Therapeutics in the fourth quarter valued at about $33,000. Finally, KBC Group NV acquired a new stake in shares of Nurix Therapeutics during the 1st quarter worth about $34,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.